Selank Guide for a 10 mg Vial

This Selank guide explains how a 10 mg vial can be calculated for intranasal research with a verified 0.10 mL metered actuator. Published human Selank studies primarily used intranasal drops or measured intranasal solution. A measured 5 mL final volume provides 200 mcg per spray, while a measured 10 mL final volume provides 100 mcg per spray.

Research context: Human studies used different amounts, durations, delivery methods, and research conditions.

Selank is a synthetic heptapeptide based on the naturally occurring tuftsin sequence. Human research has evaluated intranasal Selank in adults with generalized anxiety disorder, neurasthenia, and in acute neuroimaging experiments. The calculations below use the entire 5 mg vial and keep published study protocols separate from worked preparation examples.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Selank Peptide: Benefits, Uses, Side Effects, Research Guide.

Selank 10 mg intranasal research calculations for 5 mL and 10 mL final volumes

Selank 10 mg Nasal Spray Calculations

Both options begin with 3.0 mL in the peptide vial. Transfer the complete solution, then add enough vehicle to reach the measured final volume.

Measured Final Volume	Vehicle Added After Transfer	Final Concentration	Per Verified 0.10 mL Spray
5.0 mL	About 2.0 mL	2,000 mcg/mL	200 mcg
10.0 mL	About 7.0 mL	1,000 mcg/mL	100 mcg

Calculation basis: Each row uses the full 10 mg vial and a pump verified to release 0.10 mL per complete actuation. Nominal spray counts are calculated before priming and normal residual hold-up.

How to Prepare the 5 mL or 10 mL Research Bottle

1. Confirm the 10 mg vial, selected sterile research vehicle, actuator bottle capacity, and documented pump output.
2.Add 3.0 mL of compatible sterile vehicle to the vial with aseptic transfer technique.
3. Gently swirl until the contents are dissolved. Do not shake.
4. Transfer the complete 3.0 mL solution into a sterile 5 mL or 10 mL nasal actuator bottle.
5. Add enough vehicle to reach a measured final volume of exactly 5.0 mL or 10.0 mL. The theoretical additions are approximately 2.0 mL and 7.0 mL.
6. Secure the pump and label the bottle with the peptide amount, final volume, concentration, pump output, and preparation date.
7. Prime the pump according to the actuator instructions and record the priming sprays in the research log.
Vehicle context: The worked example can use sterile 0.9% saline as a research vehicle. Certain manufactured Selank formulations may use different excipients and concentrations, so this saline example should not be considered identical to a manufactured drop formulation.

Mathematical Actuator Equivalents

Literature Amount	5 mL Option	10 mL Option
300 mcg	1.5 theoretical sprays	3 sprays
900 mcg	4.5 theoretical sprays	9 sprays
2700 mcg	13.5 theoretical sprays	27 sprays

Note: These rows are concentration conversions, not a universal schedule. The larger actuation counts show why amounts reported with a manufactured drop formulation should not be treated as direct generic-pump instructions.

Important: Use the measured final volume and verified actuator output in every calculation. Bottle capacity alone not establish the final volume or the amount delivered per spray.

Human Selank research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable.

Source	Research Context	Published Intranasal Amount and Formulation
Zozulia et al., 2008	62 adults with generalized anxiety disorder or neurasthenia	Selank 0.15% nasal drops at 2.7 mg per day, reported as 36 drops divided across three administrations, with outcomes followed through day 14.
Syunyakov et al., 2012	20 adults with generalized anxiety disorder	2,700 mcg per day intranasally. The pharmaco-EEG analysis also examined a single 900 mcg exposure.
Panikratova et al., 2020	Healthy-volunteer functional connectivity study	One intranasal exposure using 0.15% Selank solution, 60 microliters per nostril, described as a 0.2 mg total amount.

Reported Selank formulations may vary by concentration, excipients, delivery method, and preparation. Amounts reported in published research should not be treated as direct equivalents to a different metered pump system.

Reference concentration: Mathematically, 10 mg brought to about 6.67 mL equals 1.5 mg/mL. A verified 0.10 mL actuation at that concentration contains 150 mcg. This is a concentration comparison, not of any specific finished formulation.

A 0.10 mL actuator is a common nasal pump configuration, but pump output is not universal. Published pharmaceutical research reports pump volumes across different ranges depending on device design. Use the documented specification or a validated measurement for the exact device.

mcg per spray = (10,000 mcg / final volume in mL) × verified mL per spray

Nominal sprays = final volume in mL / verified mL per spray

Output	5 mL Option	10 mL Option
0.05 mL	100 mcg	50 mcg
0.10 mL	200 mcg	100 mcg
0.13 mL	260 mcg	130 mcg

Confirm the stated volume per full actuation for the specific pump.
Follow the documented priming and repriming procedure.
Record residual volume and tail-off near bottle exhaustion when estimating usable sprays.
Keep pump orientation and actuation stroke consistent during the research procedure.

Pump delivery, priming, delivery consistency, and bottle exhaustion are important performance variables when evaluating nasal spray systems.

Use one complete set of measured and sterile research supplies for each prepared Selank 5 mg nasal bottle.

Selank 10 mg research vial One vial per prepared bottle, with lot-specific identity, purity, and assay documentation.
Sterile research vehicle: Single-use sterile 0.9% sodium chloride for the worked saline example, or another validated sterile nasal research vehicle.
Sterile nasal actuator bottle: One 5 mL or 10 mL bottle intended for research use.
Metered pump: A compatible actuator documented or verified at 0.10 mL per complete spray.
Calibrated transfer tools: Sterile measuring tools that can measure the initial 3.0 mL and the exact 5.0 mL or 10.0 mL final volume.
Clean handling supplies: Alcohol preparation pads, clean gloves, and a disinfected work surface.
Label and research log: Record the peptide amount, final volume, concentration, pump output, preparation date, priming sprays, and actuation count.
Storage materials: Light-protective, temperature-controlled storage appropriate to the validated formulation.

Quick reference for the intranasal Selank 5 mg calculation.

Human research route: Intranasal drops or solution.
Peptide amount: 10,000 mcg total in vial.
5 mL option: 2,000 mcg/mL and 100 mcg per verified 0.10 mL spray.
10 mL option: 1,000 mcg/mLand 50 mcg per verified 0.10 mL spray.
Final-volume rule: Bring the transferred solution to an exact measured final volume.

Mathematical equivalents for a verified 0.10 mL actuator.

300 mcg: 1.5 theoretical sprays at 5 mL or 3 sprays at 10 mL.
900 mcg: 4.5 theoretical sprays at 5 mL or 9 sprays at 10 mL.
2,700 mcg: 13.5 theoretical sprays at 5 mL or 27 sprays at 10 mL.
Whole vial: 50 nominal sprays at 5 mL or 100 nominal sprays at 10 mL.
Interpretation: Match each amount to its original study, delivery method, and formulation context.

Storage depends on the complete formulation, container, and handling method.

Formulation-specific storage: Storage conditions should be based on the validated stability information for the specific preparation, including container type, formulation characteristics, and handling conditions.
Research preparation storage: Use formulation-specific stability and microbiological controls rather than applying storage information from a different preparation.
Labeling: Record preparation date, final volume, concentration, vehicle, and storage conditions.

Small measurement and device details can materially change the amount delivered per spray.

Use a measured final volume, not the bottle capacity mark alone.
Verify that the actuator releases 0.10 mL per full stroke before applying the main table.
Prime and reprime according to the documented pump procedure, then record those actuations.
Keep the bottle upright and use a complete, consistent stroke for each recorded spray.
Treat the theoretical 50 or 100 sprays as nominal counts because priming and residual hold-up consume part of the volume.
A 10 mg vial contains 10,000 mcg total. Calculate the complete peptide requirement before modeling any published research protocol.
Use a validated laboratory handling and stability plan for any custom preparation.

Selank is a synthetic heptapeptide based on the tuftsin sequence. Human studies have examined anxiety-related clinical measures, leu-enkephalin metabolism, EEG response patterns, and functional brain connectivity after Selank exposure.

Intranasal drops or solution are the delivery methods reported in the primary human research summarized on this page.

The vial calculation is concentration based. Dividing 5,000 mcg by the measured final volume gives mcg per mL. Multiplying that concentration by the verified pump output gives mcg per spray.

Selank findings should be read together with the population, amount, formulation, and study design.

A comparative study reported similar anxiety-related effects for Selank and medazepam, with additional anti-asthenic and psychostimulant observations in the Selank group.
A GAD study reported different response patterns among participants, including both rapid and gradual response groups during the observation period.
A healthy-volunteer neuroimaging study examined functional connectivity after one intranasal Selank exposure rather than a repeated clinical course.
Reported adverse effects in research contexts have included unpleasant taste sensations and possible allergic reactions.
Pump output, formulation, nasal condition, and device technique can affect the delivered amount and deposition pattern.

Consistent technique improves the value of recorded research observations.

Pump specification: Record the stated or measured mL per actuation.
Priming status: Document first use, repriming, and any missed sprays.
Actuation technique: Keep bottle orientation, stroke length, and stroke force consistent.
Nasal condition: Record congestion, irritation, or other conditions that could affect deposition.
Formulation details: Record the vehicle, final volume, concentration, container, and storage conditions.
Actuation count: Track sprays from priming through final use to identify tail-off and residual volume.

Use a standardized device procedure so the recorded amount remains consistent across research observations.

Inspect the labeled concentration and confirm the actuator output before use.
Prime or reprime the pump according to the documented device procedure.
Keep the bottle in the specified orientation and use one complete, smooth stroke.
Record each actuation immediately, including priming sprays.
Wipe the nozzle with a clean material appropriate for the device and replace the cap.
Return the bottle to its documented storage condition after the research procedure.

This content is intended for educational research purposes only and does not constitute medical advice, diagnosis, or treatment. Selank is intended for research use only and is not approved for human therapeutic use. Always consult qualified healthcare professionals before considering any peptide-related therapy.

The following information provides general educational context related to scientific discussions and available background materials.

Zozulia et al. (2008)

– Human comparative study of Selank in adults with generalized anxiety disorder or neurasthenia. The study reports the 0.15% nasal-drop protocol and 2.7 mg daily amount.

Syunyakov et al. (2012)

— Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic Selank. Reports 2,700 mcg per day intranasally and a 900 mcg pharmaco-EEG exposure.

Panikratova et al. (2020)

— Functional connectomic study of acute intranasal Selank exposure in healthy volunteers.

Trows et al. (2014)

– Analytical challenges and regulatory requirements for nasal in Europe and the United States. Reviews pump output and device variables.

U.S. Food Administration

— Nasal Spray and Inhalation Solution, Suspension, and Spray Guidance covering pump delivery, priming, delivery consistency, and performance variables.

Medvedev et al. (2014)

— Randomized human comparison of Selank and phenazepam in anxiety-spectrum disorders. Reports Selank at 2.7 mg per day for 14 days.